Guadecitabine (SGI-110)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Guadecitabine (SGI-110), covering 2023-05-18 to 2026-01-29. Get the full timeline:
Most recent: Clinical Trial Update: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed [Phase 1, Phase 2]